Barcelona’s Ona takes aim at metastasis with €30M series A

Round from European syndicate is designed to deliver initial clinical results from basket trial

A European investor syndicate has funded Ona with €30 million ($33.8 million) to develop an antibody program targeting a lipid metabolism pathway whose inhibition has been associated with prevention of metastasis.

Barcelona-based Asabys Partners, which was Ona Therapeutics’ seed investor, participated

Read the full 404 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers